Merck & Co., Inc. (MRK)
NYSE: MRK · IEX Real-Time Price · USD
127.72
-0.18 (-0.14%)
At close: Jul 2, 2024, 4:00 PM
129.00
+1.28 (1.00%)
After-hours: Jul 2, 2024, 7:57 PM EDT
Merck & Co. Revenue
Merck & Co. had revenue of $61.40B in the twelve months ending March 31, 2024, with 6.11% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $15.78B with 8.89% year-over-year growth. In the year 2023, Merck & Co. had annual revenue of $60.12B with 1.40% growth.
Revenue (ttm)
$61.40B
Revenue Growth
+6.11%
P/S Ratio
5.27
Revenue / Employee
$852,806
Employees
72,000
Market Cap
323.49B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
Dec 31, 2018 | 42.29B | 2.17B | 5.41% |
Dec 31, 2017 | 40.12B | 315.00M | 0.79% |
Dec 31, 2016 | 39.81B | 309.00M | 0.78% |
Dec 31, 2015 | 39.50B | -2.74B | -6.48% |
Dec 31, 2014 | 42.24B | -1.80B | -4.08% |
Dec 31, 2013 | 44.03B | -3.23B | -6.84% |
Dec 31, 2012 | 47.27B | -780.00M | -1.62% |
Dec 31, 2011 | 48.05B | 2.06B | 4.48% |
Dec 31, 2010 | 45.99B | 18.56B | 67.66% |
Dec 31, 2009 | 27.43B | 3.58B | 15.00% |
Dec 31, 2008 | 23.85B | -347.70M | -1.44% |
Dec 31, 2007 | 24.20B | 1.56B | 6.90% |
Dec 31, 2006 | 22.64B | 624.10M | 2.84% |
Dec 31, 2005 | 22.01B | -960.90M | -4.18% |
Dec 31, 2004 | 22.97B | 486.90M | 2.17% |
Dec 31, 2003 | 22.49B | 1.04B | 4.85% |
Dec 31, 2002 | 21.45B | 246.80M | 1.16% |
Dec 31, 2001 | 21.20B | -19.16B | -47.48% |
Dec 31, 2000 | 40.36B | 7.65B | 23.38% |
Dec 31, 1999 | 32.71B | 5.82B | 21.62% |
Dec 31, 1998 | 26.90B | 3.26B | 13.80% |
Dec 31, 1997 | 23.64B | 3.81B | 19.21% |
Dec 31, 1996 | 19.83B | 3.15B | 18.87% |
Dec 31, 1995 | 16.68B | 1.71B | 11.43% |
Dec 31, 1994 | 14.97B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
AbbVie | 54.40B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
Eli Lilly | 35.93B |
MRK News
- 1 day ago - N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials - Business Wire
- 1 day ago - Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer - Business Wire
- 1 day ago - Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30 - Business Wire
- 4 days ago - Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH) - Business Wire
- 4 days ago - Global Bioreactors Market Forecast Report 2024-2035 with Key Players Profiles of Applikon Biotechnology, Bionet, Cytiva, Eppendorf, Merck, Sartorius, Solaris Biotech, Solida Biotech and LABAO - GlobeNewsWire
- 5 days ago - CDC'S ACIP Unanimously Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults - Business Wire
- 5 days ago - Merck Stock Is Slipping. A CDC Committee Considers Pneumococcal Vaccines. - Barrons
- 5 days ago - US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug - Reuters